Odonate Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ODTC research report →
Companywww.odonate.com
Odonate Therapeutics, Inc. , a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer.
- CEO
- Kevin C. Tang
- IPO
- 2017
- Employees
- 137
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $8.05B
- P/E
- 3227.30
- P/S
- 0.00
- P/B
- 218.64
- EV/EBITDA
- 846.16
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 7.01%
- ROIC
- -0.57%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $7.33M · -82.94%
- EPS
- $6.82 · -99.98%
- Op Income
- $-817,000
- FCF YoY
- 386.91%
Performance & Tape
- 52W High
- $358000.00
- 52W Low
- $22005.00
- 50D MA
- $150188.00
- 200D MA
- $139977.00
- Beta
- 0.41
- Avg Volume
- 0
Get TickerSpark's AI analysis on ODTC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ODTC Coverage
We haven't published any research on ODTC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ODTC Report →